# Central Advisory Panel Moves to Curb Illicit and Fake Habit-Forming Drugs with State-Level Tracking > The Drugs Consultative Committee has recommended monthly state reporting and a unified digital tracking database to prevent the diversion of narcotic and psychotropic medicines. **Type:** article · **Category:** India · **Published:** 2026-10-02 · **Source:** TrendKia **Canonical:** https://trendkia.com/en/national/pharji-aura-nashili-davaon-para-nakela-kasane-ke-lie-kendra-ka-naya-rodamaipa-rajyon-se-manga-masika-hisaba-41871 · **Language:** English **Tags:** CDSCO, Drugs Consultative Committee, Narcotic Drugs, Spurious Drugs, DCGI, Pharma Regulation A comprehensive regulatory framework has been initiated to clamp down on the illicit trafficking, illegal diversion, and unauthorized use of spurious and habit-forming pharmaceuticals across the country. The government's apex drug advisory body has recommended sweeping measures to tighten supervision over medicines containing narcotic and psychotropic substances. This initiative forms an integral component of the Vision Document on Drug Control spanning 2026 to 2029, with the central authorities formally seeking active cooperation from state administrations to implement the safeguards. ## Roadmap Unveiled at Narco Coordination Center Meeting The vision document serves as a strategic medium-term roadmap designed to overhaul pharmaceutical enforcement and control mechanisms in the coming years. It was formally unveiled during the 10th apex-level meeting of the Narco Coordination Center, an administrative mechanism operating under the Ministry of Home Affairs tasked with coordinating inter-agency enforcement measures against narcotics. The broader mandate focuses on eliminating loopholes that allow medicinal formulations to be diverted into illicit consumption channels. ## CDSCO Assigned Regulatory Deadline for March 2027 India's central drug authority, the Central Drugs Standard Control Organisation, has been assigned a definitive institutional milestone under this initiative. By March 2027, the regulator is required to eliminate existing regulatory gaps and enforcement vulnerabilities associated with the unlawful diversion of pharmaceutical preparations containing narcotic drugs and psychotropic compounds. To fulfill this objective, the expert committee emphasized the necessity of constructing an authenticated national database. This centralized repository will systematically record the manufacture, commercial distribution, inventory stocking, site inspections, and punitive enforcement actions concerning such controlled formulations. The advisory panel instructed the central regulator to assemble all existing statutory directions, state-level regulatory measures, and standard operating procedures to formulate a cohesive operational strategy. ## Monthly State Audits and Integrated Digital Tracking Under the proposed oversight structure, states and union territories will be mandated to furnish regular monthly dossiers to the central regulator. These submissions will require detailed disclosures regarding the exact number of licenses granted, the aggregate volume of controlled substances handled, the volume of regulatory site inspections conducted, and the specific enforcement penalties imposed. The precise compliance format will be established following detailed consultations with regional state regulators. The committee recommended that this tracking architecture reside on a shared digital platform capable of real-time data aggregation and trend analytics. It further suggested assessing the feasibility of adopting the existing online tracking system established by the Central Bureau of Narcotics. Deploying such digital infrastructure would enable comprehensive track-and-trace capabilities spanning the entire supply chain, starting from pharmaceutical production facilities down to retail chemist counters. These recommendations remain subject to formal ratification, as their implementation is contingent upon approval by the Drug Controller General of India, who heads the central drug regulatory authority. ## Action on National Human Rights Commission Recommendations Parallel enforcement steps are underway concerning substandard and counterfeit medical products. On February 25, the National Human Rights Commission convened an open dialogue to deliberate on curbs against spurious drugs, subsequently transmitting its recommendations to the Drugs Consultative Committee. Upon assessment, the advisory committee observed that while several recommendations were already active, other proposals necessitate substantive state-level inputs and inter-departmental synergy. The official meeting minutes underscored that effective deterrence requires synchronized intervention involving regional drug inspectors, state police personnel, analytical testing laboratories, prosecuting agencies, and forensic institutions. Consequently, the panel decided to circulate the commission's comprehensive recommendations to all state and union territory governments. These regional administrations will be requested to submit observations, details of preventive measures already implemented within their jurisdictions, and specific inputs on the proposed national mechanism. Following receipt of these inputs, the central regulator will draft a consolidated proposal, while a select working group representing designated states will prepare the formal response and operational roadmap for submission to the rights body. ## What this means for you Tighter national tracking of controlled and spurious medicines significantly enhances consumer safety by ensuring authenticity in the pharmaceutical supply chain. - **Medicine Authenticity:** Comprehensive track-and-trace mechanisms from manufacturing plants to retail chemists curb the entry of counterfeit products into the retail market. Patients are assured of receiving verified medical preparations, preventing life-threatening risks associated with spurious formulations. - **Prescription Rigor:** Heightened supervision over narcotic and psychotropic formulations will enforce strict adherence to mandatory prescription requirements at retail counters. Consumers will no longer be able to procure habit-forming pain management medicines or potent formulations over the counter. - **Local Enforcement Audits:** State administrations and regional drug enforcement wings will ramp up retail inspections and stock verifications. Retailers found diverting medicines or maintaining unauthorized inventories will face immediate license cancellations and legal action. - **Supply Chain Transparency:** Centralized digital documentation minimizes artificial local shortages of essential critical-care formulations. Legitimate patients requiring specialized pain management therapies will access genuine inventory without disruptions. ## Why this happened This regulatory overhaul was prompted by increasing concerns over counterfeit pharmaceuticals and the illicit diversion of therapeutic habit-forming medicines into the narcotics trade. - **Regulatory Gaps and Divergence:** Existing supervisory deficiencies in the pharmaceutical distribution chain allowed therapeutic formulations containing controlled compounds to leak into the contraband market. The initiative seeks to systematically eliminate these vulnerabilities by March 2027. - **Human Rights Commission Scrutiny:** The National Human Rights Commission convened an open dialogue on February 25 to highlight public health hazards posed by spurious drugs. Its formal recommendations pushed the advisory panel to pursue coordinated national enforcement. - **Inter-Agency Fragmentation:** A lack of structured information sharing between state drug inspectors, law enforcement agencies, testing labs, and forensic bodies previously weakened regulatory outcomes. Establishing centralized digital tracking and state-level consultation addresses this structural defect. ## Questions & Answers ### 1. Which categories of pharmaceuticals are targeted for stricter supervision? The advisory panel has recommended strict monitoring over medicinal preparations containing narcotic and psychotropic substances. ### 2. What deadline has been assigned to CDSCO for tightening regulatory oversight? CDSCO has been tasked with eliminating regulatory gaps regarding the unlawful diversion of controlled pharmaceutical preparations by March 2027. ### 3. What data must states and union territories submit in their monthly reports? States must report the number of licenses issued, quantities of controlled drugs handled, inspections conducted, and enforcement actions taken. ### 4. What digital infrastructure has been recommended for tracking medicines? The panel recommended a shared digital platform, suggesting the adoption of the Central Bureau of Narcotics portal for end-to-end supply chain tracking. ### 5. When did the National Human Rights Commission conduct its dialogue on spurious drugs? The National Human Rights Commission held an open discussion on curbing spurious medicines on February 25. --- _TrendKia — Har trend, sabse pehle.. Machine-readable view; canonical HTML at the URL above._